|
|
| It’s not magic -- it’s science. | With KBI Biopharma’s SUREmAb™ solution, your mAb development moves faster and smarter. Get minimum titers of 4 g/L and up to 10g/L for your IgG monoclonal antibodies before process optimization and tox material in just 6.5 months from transfection—guaranteed. Built on the SUREtechnology Platform™, powered by Selexis®, that has enabled bringing over 110 mAbs to clinic and 7 to market. Set your mAb program on the fast track. |
|
|
|
|
By Matthew Pillar, Editor, Bioprocess Online
| Complex protein therapeutic innovators are often orchestrating the work of three, four, or more outsourced manufacturing partners at once. What goes into their selection criteria? Experts from ADC and fusion protein sponsors weigh in, with bonus commentary from a CDMO process development specialist. |
|
|
| A Feeder-Free Platform For Generating Mature Natural Killer Cells | White Paper | By Raymond Wu, Ph.D., Joshua Gutierrez, Venkatesh Natarajan, Ph.D., and Frank Luh, Theragent | NK cells represent a promising avenue for immunotherapy. Examine the advantages of NK cells in cellular immunotherapy and the importance of developing efficient activation and expansion platforms. |
|
|
| The High Cost Of Going Cheap | Article | By Jessica Carmen, Ph.D., Kincell Bio | Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors. |
|
|
|
|
|
| 3 Key Trends Shaping The CDMO Industry | Article | By Cory Lewis, INCOG BioPharma Services | It is essential for biopharma companies to stay up to date on the future of CDMOs. Read about three key trends that are helping shape the CDMO industry. |
|
|
|
| Current And Emerging Technologies To Optimize mRNA Manufacturing | Article | By Clemens Jakobi, Michał Domański, and Telmo Graça, Lonza | Explore the benefits of using mRNA for vaccines and therapeutics, and learn how to address technical, intellectual property, and cost considerations when considering commercial production. |
|
|
|
|
|
|
|
|
|
| Webinar: Introducing Two New Highly Effective ADC Payloads For Cancer Therapeutics | Despite increasing interest in ADC drug development, access to safe and effective therapeutic agents (also known as payloads) and linkers is limited. Join us November 6th to learn more about Samsung Biologics’ two novel ADC payloads that demonstrate best-in-class efficacy and safety profiles upon extensive characterizations in vitro and in vivo. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
